Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38

BackgroundCD38 and CD47 are expressed in many hematologic malignancies, including multiple myeloma (MM), B-cell non-Hodgkin lymphoma (NHL), B-cell acute lymphoblastic leukemia (ALL), and B-cell chronic lymphocytic leukemia (CLL). Here, we evaluated the antitumor activities of CD38/CD47 bispecific an...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Frontiers in Immunology
المؤلفون الرئيسيون:	Song Li, Dianze Chen, Yanan Yang, Huiqin Guo, Dandan Liu, Nana Sun, Xing Bai, Kaili Wang, Tengfei Li, Guanghui Li, Chunmei Yang, Wei Zhang, Li Zhang, Gui Zhao, Liang Peng, Sijin Liu, Xiaoping Tu, Ruliang Zhang, Wenzhi Tian
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Frontiers Media S.A. 2024-06-01
الموضوعات:	CD38 cd47 CD38/CD47 bispecific antibody hematologic malignancies Fc-mediated effector function Apoptosis
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1398508/full